Improved diagnosis of meningococcal, pneumococcal and group A streptococcal infections

Please note, this collection consists of blood clots but it is listed as plasma. Study to demonstrate the efficacy of GlaxoSmithKline Biologicals’ quadrivalent seasonal influenza candidate vaccine GSK2321138A (FLU D-QIV), administered intramuscularly in children 9 to 35 months of age.

Please note, this collection consists of blood clots but it is listed as plasma. During the initial study your child received one of 2 pneumococcal vaccines; either the 7-valent pneumococcal vaccine (PCV7) which protects against 7 types of pneumococcal bacteria, or the new 13-valent pneumococcal vaccine (PCV13) protecting against 13 types of pneumococcus which has recently replaced PCV7 in the routine immunisation schedule. The PCV13 vaccine has been shown to produce an immune response against 13 types of pneumococcus and therefore provides a broader level of protection than the PCV7 vaccine. It is now important to determine how well the immune response to the PCV13 vaccine persists throughout childhood. To do this we would like to take a sample of blood from children, who participated in the original study, when they are approximately 3 ½ years of age. We would also like to study the response to a dose of PCV13 vaccine when given to children who were immunised with either PCV7 or PCV13 as an infant.